IP Library › Granted Patent US 10,428,071
Granted Patent B2
US 10,428,071 · App. 16/071,666 · Granted Oct 1, 2019

Carboline derivative serving as bromodomain inhibitor

Inventor: Nenghui Wang (Zhejiang, CN)
Assignee: NINGBO WENDA PHARMA TECHNOLOY LTD.
C07D471/14A61K31/437C07D471/04A61P31/12A61P35/02A61P37/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,428,071
App. No.
16/071,666
Granted
Oct 1, 2019
Kind
B2
Abstract

Disclosed in the present invention is a carboline derivative serving as an bromodomain inhibitor. The carboline derivative in the present invention can be used as an bromodomain inhibitor, and can provide a method and a pharmaceutical composition for controlling diseases intervened by a bromodomain protein.

Claims (3)

1. A carboline derivative selected from the group consisting of

or a salt thereof.

2. A pharmaceutical composition, comprising: (i) a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and (ii) a pharmaceutically acceptable carrier.

Assignments (2)
CHANGE OF NAME Recorded Aug 22, 2022
From: NINGBO WENDA PHARMA TECHNOLOY LTD.
To: ZHEJIANG WENDA PHARMACEUTICAL TECHNOLOGY CO., LTD
Reel/Frame 061295/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2018
From: WANG, NENGHUI
To: NINGBO WENDA PHARMA TECHNOLOY LTD.
Reel/Frame 046805/0124 →
Priority Claims (1)
CN 2016 1 0038402 · Jan 20, 2016 · national
Continuity (1)
Related Publication 20190031660A1 · Jan 31, 2019